Sugi Predict

Sugi Predict / Compounds / SCHEMBL8665

SCHEMBL8665

SCHEMBL8665

O=c1c(-c2ccccc2)c(CBr)oc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 7/20 0.59
▸ CA2 P00918 7/20 0.59
▸ MAPT P10636 2/20 0.51
▸ KDM4E B2RXH2 4/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ GLA P06280 1/20 0.48
▸ PGAM1 P18669 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ PLA2G2A P14555 1/20 0.48
▸ PLA2G4A P47712 1/20 0.48
▸ CA12 O43570 2/20 0.47
▸ TP53 P04637 2/20 0.47
▸ ABCB1 P08183 2/20 0.47
▸ AR P10275 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8435 0.89 MAPK14 (0.56) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL9311 0.88 CA1 (0.56) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL9595 0.85 CA1 (0.54) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL9363 0.84 GABRP (0.52) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL27501502 0.84 CA1 (0.59) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL8733 0.84 CA1 (0.59) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL9282 0.84 TNKS (0.52) CA1CA2MAPTADORA3KMT2A
SCHEMBL8257 0.84 GABRP (0.52) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL8612 0.81 CA1 (0.56) CA1CA2MAPTKDM4ECYP3A4
SCHEMBL15527966 0.81 CA1 (0.56) CA1CA2MAPTKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US disclosed
US-7312344-B2 Dimeric isoflavones NOVOGEN RESEARCH PTY LIMITED (AU) 2007-12-25 — — US disclosed
EP-1373242-A4 DIMERIC ISOFLAVONES NOVOGEN RES PTY LTD (AU) 2005-08-24 — — EP disclosed
US-20040152761-A1 Dimeric isoflavones NOVOGEN RESEARCH PTY LIMITED (AU) 2004-08-05 — — US disclosed
EP-1373242-A1 DIMERIC ISOFLAVONES Novogen Research Pty. Ltd. (AU) 2004-01-02 — — EP disclosed
WO-2002070502-A1 DIMERIC ISOFLAVONES NOVOGEN RESEARCH PTY LTD (AU) 2002-09-12 — — WO disclosed
US-6087385-A AN ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS FOR THE TREATMENT OF CERTAIN ENDOCRINE DISEASES LIKE DIABETES, PROSTATE CANCER, BREAST CANCER, PSORIASIS, ACNE, CERTAIN CARDIOVASCULAR DISORDERS INCLUDING HYPERTENSION UNIVERSITY OF MISSISSIPPI (US) 2000-07-11 — — US disclosed
US-6028088-A USEFUL AS ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS; FOR TREATMENT OF CERTAIN ENDOCRINE DISEASES INCLUDING DIABETES, CERTAIN MALIGNANT AND NON-MALIGNANT PROLIFERATIVE DISEASES INCLUDING PROSTATE CANCER THE UNIVERSITY OF MISSISSIPPI (US) 2000-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 CA1 4598/4885CA2 3153/4885MAPT 2596/4885
US-20040152761-A1 Dimeric isoflavones NR5A1, NR0B1, NR4A1 CA1 3634/4885CA2 4678/4885MAPT 4598/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885MAPT 2989/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885MAPT 2989/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885MAPT 2989/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A CA1 4543/4885CA2 3288/4885MAPT 3674/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885MAPT 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.